Search | Clinical Trials Finder

Conditions: Non-muscle Invasive Bladder Cancer
Interventions: anti-CD40 antibody 2141-V11, Intravesical Gemcitabine, Intravesical Gemcitabine with anti-CD40 antibody 2141-V11; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 115 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: Previously Untreated Relapsed Refractory Acute Myeloid Leukemia
Interventions: Samalizumab (BAML-16-001-S1), BI 836858 (BAML-16-001-S2), Laboratory Biomarker Analysis, Daunorubicin (BAML-16-001-S1), Cytarabine (BAML-16-001-S1), Azacitidine (BAML-16-001-S2), AG-221 (BAML-16-001-S3), Azacitidine (BAML-16-001-S3), Entospletinib (BAML-16-001-S4), Azacitidine (BAML-16-001-S4), Entospletinib (BAML-16-001-S5), Decitabine (BAML-16-001-S5), Entospletinib (BAML-16-001-S6), Daunorubicin (BAML-16-001-S6), Cytarabine (BAML-16-001-S6), Pevonedistat (BAML-16-001-S9), Azacitidine (BAML-16-001-S9), AG-120 (BAML-16-001-S16), Azacitidine (BAML-16-001-S16), Gilteritinib (BAML-16-001-S8 Group 1), Decitabine (BAML-16-001-S8 Group 1), AZD5153 (BAML-16-001-S10), Venetoclax (BAML-16-001-S10), TP-0903 (BAML-16-001-S14), Decitabine (BAML-16-001-S14), Decitabine (BAML-16-001-S8 Group 2), Venetoclax (BAML-16-001-S8 Group 2), AZD5991 (BAML-16-001-S18), Azacitidine (BAML-16-001-S18), SNDX-5613 (BAML-16-001-S17), Azacitidine (BAML-16-001-S17), Venetoclax (BAML-16-001-S17), Gilteritinib (BAML-16-001-S8 Group 2), Venetoclax (BAML-16-001-S12 Arm A), Azacitidine (BAML-16-001-S12 Arm A), Venetoclax (BAML-16-001-S12 Arm B), Azacitidine (BAML-16-001-S12 Arm B), ZE46-0134 (BAML-16-001-S21 Group 1), ficlatuzumab (BAML-16-001-S24), Azacitidine (BAML-16-001-S24), Venetoclax (BAML-16-001-S24), ZE46-0134 (BAML-16-001-S21 Group 2), Bleximenib (BAML-16-001-S25/HO181), Cytarabine (BAML-16-001-S25/HO181), Daunorubicin or Idarubicin (BAML-16-001-S25/HO181), Placebo (BAML-16-001-S25/HO181), Revumenib (BAML-16-001-S26/HO177), Placebo (BAML-16-001-S26/HO177); Biological · Other · Drug
Lead sponsor: Beat AML, LLC; Other
Eligibility: 18 Years and older
Enrollment: 3,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2032
U.S. locations: 31
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Los Angeles, California + 26 more

Conditions: Diabetic Macular Edema, Uveitic Macular Edema
Interventions: RO7200220, Ranibizumab; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 19
States / cities: Beverly Hills, California • Oxnard, California • Palm Desert, California + 16 more

Conditions: Wet Macular Degeneration
Interventions: BI 836880; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 55 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 7
States / cities: Phoenix, Arizona • New York, New York • Eugene, Oregon + 4 more

Conditions: HER2-positive Breast Cancer, HER-2 Protein Overexpression, HER-2 Gene Amplification, HER2 Gene Mutation
Interventions: ORM-5029; Drug
Lead sponsor: Orum Therapeutics USA, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 11
States / cities: Birmingham, Alabama • Los Angeles, California • Boston, Massachusetts + 7 more

Conditions: Spinal and Bulbar Muscular Atrophy
Interventions: BVS857, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 3
States / cities: Orange, California • Bethesda, Maryland • Columbus, Ohio

Conditions: Dermatitis, Atopic
Interventions: Dupilumab, Matching placebo; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 6 Months to 5 Years
Enrollment: 202 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 33
States / cities: Birmingham, Alabama • Gilbert, Arizona • Long Beach, California + 30 more

Conditions: Acquired Immune Deficiency Syndrome (AIDS), HIV Infections
Interventions: ATV, DRV, Cobicistat, BR, F/TAF, LPV/r, Third Unboosted Drug, Cobicistat TOS, F/TAF TOS; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 4 Weeks to 17 Years
Enrollment: 133 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2027
U.S. locations: 7
States / cities: Long Beach, California • Los Angeles, California • Aurora, Colorado + 4 more

Conditions: Colon Cancer Metastatic, Head and Neck Cancer Metastatic, Metastatic Non-Small Cell Lung Cancer, Urothelial Carcinoma, Metastatic Melanoma
Interventions: ADXS-NEO, Pembrolizumab; Biological
Lead sponsor: Advaxis, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 5
States / cities: Scottsdale, Arizona • Los Angeles, California • New Orleans, Louisiana + 2 more

Conditions: Healthy Volunteer
Interventions: Genz-682452, Placebo; Drug
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 63 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Advanced Solid Tumors That Are MTAP Deficient
Interventions: AZD3470, Datopotamab deruxtecan; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 334 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 8
States / cities: San Francisco, California • West Hollywood, California • New Haven, Connecticut + 5 more

Conditions: Healthy
Interventions: P7435, Placebo; Drug · Other
Lead sponsor: Piramal Enterprises Limited; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Chula Vista, California

Conditions: Acute Kidney Injury, Renal Replacement Therapy, Pediatric Intensive Care Unit
Interventions: Furosemide Stress Test Clinical Decision Support Tool; Other
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: Not listed
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Embryonal Tumor With Multilayered Rosettes, Embryonal Tumor With Multilayered Rosettes, Nos
Interventions: Radiotherapy (RT), Chemotherapy Drug, Cancer - Physician's Choice, Non-Investigational Surgical Resection, Temozolomide, Tumor Tissue Sample, Blood Sample, Cerebrospinal Fluid (CSF) Sample; Radiation · Drug · Procedure
Lead sponsor: University of California, San Francisco; Other
Eligibility: Not listed
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 8
States / cities: Birmingham, Alabama • San Francisco, California • Indianapolis, Indiana + 5 more

Conditions: Solid Tumors
Interventions: Atezolizumab, Selicrelumab; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Healthy Volunteers
Interventions: LY2409021, Gemfibrozil, Ketoconazole, Clarithromycin; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Evansville, Indiana

Conditions: Multiple Myeloma
Interventions: Linvoseltamab; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 149 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2035
U.S. locations: 13
States / cities: Los Angeles, California • Orange, California • Denver, Colorado + 9 more

Conditions: Gastrointestinal Stromal Tumor (GIST)
Interventions: DCC-3009; Drug
Lead sponsor: Deciphera Pharmaceuticals, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 10
States / cities: Scottsdate, Arizona • La Jolla, California • Aurora, Colorado + 7 more

Conditions: B-cell Malignancy, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Waldenstrom Macroglobulinemia, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Follicular Lymphoma, Non-Hodgkin Lymphoma
Interventions: Docirbrutinib; Drug
Lead sponsor: Carna Biosciences, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 13
States / cities: Orange, California • Miami Beach, Florida • Tampa, Florida + 9 more

Conditions: Parkinson Disease
Interventions: [123I] IBVM and SPECT imaging, Subjects will undergo the 123-I IBVM imaging visit; Drug
Lead sponsor: Institute for Neurodegenerative Disorders; Other
Eligibility: 30 Years and older
Enrollment: 75 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Metastatic Colorectal Cancer
Interventions: SPLIT Abs, 203Pb-DOTAM, 212Pb-DOTAM; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2034
U.S. locations: 5
States / cities: Chicago, Illinois • St Louis, Missouri • Omaha, Nebraska + 2 more

Conditions: HIV, HIV Infections, Acquired Immunodeficiency Syndrome
Interventions: TAF, Placebo, E/C/F/TAF, Current failing ARV regimen, ATV; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 5
States / cities: Ft. Pierce, Florida • West Palm Beach, Florida • Wilton Manors, Florida + 2 more

Conditions: Advanced Solid Tumors
Interventions: BMS-986466, Adagrasib, Cetuximab; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 4
States / cities: Los Angeles, California • Athens, Georgia • Hackensack, New Jersey + 1 more

Conditions: Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL), Relapsed or Refractory Multiple Myeloma (MM)
Interventions: Lymphodepleting chemotherapy: Cyclophosphamide, Lymphodepleting chemotherapy: Bendamustine, Lymphodepleting chemotherapy: Fludarabine, Lisocabtagene Maraleucel, Axicabtagene Ciloleucel, Ciltacabtagene Autoleucel, Low-Dose Total Body Irradiation; Drug · Other · Radiation
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2033
U.S. locations: 1
States / cities: New York, New York

Search by objective public record fields.

Study of 2141-V11 in People With Non-muscle Invasive Bladder Cancer That Did Not Respond to Standard Treatment

Study of Biomarker-Based Treatment of Acute Myeloid Leukemia

A Study to Investigate RO7200220 as Monotherapy and in Combination With Ranibizumab in Participants With Diabetic and Uveitic Macular Edema

A Study to Test Different Doses of BI 836880 in Patients With an Eye Disease Called Wet Age-related Macular Degeneration (wAMD)

Study of ORM-5029 in Subjects With HER2-Expressing Advanced Solid Tumors

Safety, Tolerability, and Efficacy of BVS857 in Patients With Spinal and Bulbar Muscular Atrophy

Safety, Pharmacokinetics and Efficacy of Dupilumab in Patients ≥6 Months to <6 Years With Moderate-to-Severe Atopic Dermatitis (Liberty AD PRESCHOOL)

Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV

A Study of ADXS-NEO Expressing Personalized Tumor Antigens

Safety, Tolerability and Pharmacokinetics of Genz-682452 in Healthy Men

A Study of AZD3470, a PRMT5 Inhibitor, Given as Monotherapy and in Combination in Patients With MTAP Deficient Advanced/Metastatic Solid Tumors

Study to Determine the Safety, Tolerability, Pharmacokinetics, Food Effect and Pharmacodynamics of Single and Multiple Ascending Doses of P7435 in Healthy, Overweight or Obese Subjects

FST Analysis Supporting Timely Therapy and Risk Assessment Via Clinical Decision Support for Kids

Embryonal Tumor With Multilayered Rosettes

A Study of Selicrelumab (RO7009789) in Combination With Atezolizumab in Participants With Locally Advanced and/or Metastatic Solid Tumors

The Effect of Gemfibrozil, Ketoconazole and Clarithromycin on the Amount of LY2409021 in the Bloodstream

A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment

A Master Protocol to Evaluate DCC-3009 in Gastrointestinal Stromal Tumor (GIST)

AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma

Development of Cognitive Assessment Tools in Parkinson Disease

A Study to Investigate CEA-PRIT 2.0 in Participants With Metastatic Colorectal Cancer (mCRC)

Efficacy of Tenofovir Alafenamide Versus Placebo Added to a Failing Regimen Followed by Treatment With Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Plus Atazanavir in HIV-1 Positive, Antiretroviral Treatment-Experienced Adults

A Study of BMS-986466 With Adagrasib With or Without Cetuximab in Participants With Kirsten Rat Sarcoma Virus Glycine 12 to Cysteine (KRAS G12C)-Mutant Solid Tumors

Low-Dose TBI Plus CAR T-Cell Therapy for Relapsed/Refractory DLBCL and Multiple Myeloma